CoDa's wound care product performs well in clinical trial

01/29/2013 | (New Zealand)

CoDa Therapeutics announced that its experimental drug Nexagon to treat chronic venous leg ulcers performed well in midstage clinical trials. The therapy aims to heal wounds faster and increase the incidence of wound healing compared with existing treatment options.

View Full Article in: (New Zealand)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC